Literature DB >> 30589902

Correction: Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.

James D Allen, Satyajit Ray, Ted M Ross.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0204284.].

Entities:  

Year:  2018        PMID: 30589902      PMCID: PMC6307928          DOI: 10.1371/journal.pone.0210043

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


There is an error in Table 2. The coloring of cells in the table is incorrect. The coloring should appear as below. Additionally, “historical” is misspelled in the published table’s footnote.
Table 2

Historical vaccine strain panel (1995–2016) HAI heat map.

1:40 CutoffNan/95Syd/97Pan/99Fuj/02NY/04Wisc/05Bris/07Perth/09Vic/11Tx/12Switz/13HK/14Sing/16
PBS0000000000000
HK/140000014112057
Switz/130000000002400
Tx/120000175888678
Uru/070001488415050
Wisc/050001285023000
COBRA T70000456000006
COBRA T110000011355133
1:80 CutoffNan/95Syd/97Pan/99Fuj/02NY/04Wisc/05Bris/07Perth/09Vic/11Tx/12Switz/13HK/14Sing/16
PBS0000000000000
HK/140000003111055
Switz/130000000000300
Tx/120000065888555
Uru/070000388114050
Wisc/050000084001000
COBRA T70000156000005
COBRA T110000010254021

Numbers represent the number of animals from each group that achieved an antibody titer ≥1:40 in the (top table) and ≥1:80 (bottom table) against 13 historical H3N2 vaccine strains. Colors range from red representing 0 animals achieving the designated titer to dark green representing when all 8 animals surpassed the antibody titer cutoff.

Numbers represent the number of animals from each group that achieved an antibody titer ≥1:40 in the (top table) and ≥1:80 (bottom table) against 13 historical H3N2 vaccine strains. Colors range from red representing 0 animals achieving the designated titer to dark green representing when all 8 animals surpassed the antibody titer cutoff.
  1 in total

1.  Split inactivated COBRA vaccine elicits protective antibodies against H1N1 and H3N2 influenza viruses.

Authors:  James D Allen; Satyajit Ray; Ted M Ross
Journal:  PLoS One       Date:  2018-09-28       Impact factor: 3.240

  1 in total
  1 in total

Review 1.  From Sharks to Yeasts: Squalene in the Development of Vaccine Adjuvants.

Authors:  Adélia Mendes; João Azevedo-Silva; João C Fernandes
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.